Literature DB >> 10772813

Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus.

M S Lindström1, U Klangby, R Inoue, P Pisa, K G Wiman, C E Asker.   

Abstract

The human p14(ARF) protein is encoded by an alternative transcript from the INK4a/ARF locus on chromosome 9p21, a locus frequently afflicted in human tumors. By use of two novel specific antisera against p14(ARF) we show that the protein is localized mainly in nucleoli but also in the nucleoplasm. Transfection of full-length and deletion mutant GFP-p14(ARF) fusion proteins confirmed this subcellular localization and assigned the nucleolar localization signal to the exon 2-encoded C-terminal region. In order to determine p14(ARF) expression in human tumor cells, we examined p14(ARF) in 32 tumor cell lines by immunofluorescence staining. Nucleolar p14(ARF) was detected in 10 lines, all of which lacked functional p53. Double immunostaining with p14(ARF) and B23/nucleophosmin or fibrillarin antibodies using 3D microscopy revealed that p14(ARF) is located mainly in the granular component of the nucleolus. p14(ARF) was also found in distinct granular aggregates scattered throughout the nucleoplasm. RNase digestion or selective inhibition of rRNA transcription by low doses of actinomycin D caused nucleoplasmic translocation of p14(ARF). This indicates that the nucleolar localization of p14(ARF) is dependent on ongoing transcriptional activity in intact functional nucleoli. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772813     DOI: 10.1006/excr.2000.4854

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  20 in total

1.  Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition.

Authors:  D G Pestov; Z Strezoska; L F Lau
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

2.  Study on the spatial architecture of p53, MDM2, and p14ARF containing complexes.

Authors:  Andrej Savchenko; Mariya Yurchenko; Boris Snopok; Elena Kashuba
Journal:  Mol Biotechnol       Date:  2008-11-07       Impact factor: 2.695

3.  The DNA damage effector Chk1 kinase regulates Cdc14B nucleolar shuttling during cell cycle progression.

Authors:  Sirisha Peddibhotla; Zhubo Wei; Rao Papineni; Micheal H Lam; Jeffrey M Rosen; Pumin Zhang
Journal:  Cell Cycle       Date:  2011-02-15       Impact factor: 4.534

4.  Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis.

Authors:  Seema Paliwal; Sandhya Pande; Ramesh C Kovi; Norman E Sharpless; Nabeel Bardeesy; Steven R Grossman
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

5.  ARF function does not require p53 stabilization or Mdm2 relocalization.

Authors:  Chandrashekhar Korgaonkar; Lili Zhao; Modestos Modestou; Dawn E Quelle
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

Review 6.  DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.

Authors:  Ruth A Gjerset
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 2.611

7.  Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.

Authors:  Chandrashekhar Korgaonkar; Jussara Hagen; Van Tompkins; April A Frazier; Chantal Allamargot; Frederick W Quelle; Dawn E Quelle
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

8.  ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.

Authors:  Suzanne N Brady; Yue Yu; Leonard B Maggi; Jason D Weber
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

9.  Mitochondrial p32 is a critical mediator of ARF-induced apoptosis.

Authors:  Koji Itahana; Yanping Zhang
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

10.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.